Drug Discovery · Jersey City, NJ · Founded 2018 · Privately Held (backing)
Developer of a topical formulation technology designed to treat orphan ophthalmic disorders. Claris Bio is based in Jersey City, NJ and was founded in 2018. It was valued at $163 million at its later-stage round in Nov 2025, the last priced event on record. It has raised $154 million across 1 recorded round; the latest was a $54.5 million Series A in Jan 2024.
PMV mark · valuation
$163.4M
Oct 2026
Priced at
its later-stage round
Nov 2025
Total raised
$153.6M
Last round
Later Stage VC (Series A)
Jan 2024
No prints on record
No secondary trades in Claris Bio shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Claris Bio with a free account
·Watch Claris Bio: the Monday email on marks, rounds and moves
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Claris Bio stock.
